Eucomed fights for stand-alone regulation for HTEPs
This article was originally published in Clinica
A stand-alone new European regulation is necessary for human tissue-engineered products, or European industry will suffer globally. That is the statement that has been made by Eucomed, following the circulation of reports that HTEPs are to be regulated alongside pharmaceuticals and that the so-called "third pillar" of regulation, a unique regulatory framework for these products, has been abandoned (see Clinica Nos 1151, p 3 1153, p 3).
You may also be interested in...
Following hot on the heels of its Rapidly Manufactured Ventilator Specification document, the UK’s regulator has issued another speedy regulatory permit for fast production of respiratory assist devices.
Which drug candidates represent hope, and which hype? The Scrip team examine the COVID-19 pipeline, lessons from China, and some long term impacts on the sector.
China insists there is no double standard and won’t tolerate any quality issues in its centralized procurement process.